Sagimet Biosciences Inc [SGMT] stock is trading at $6.24, up 0.48%. An important factor to consider is whether the stock is rising or falling in short-term value. The SGMT shares have gain 12.64% over the last week, with a monthly amount drifted -1.27%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Sagimet Biosciences Inc [NASDAQ: SGMT] stock has seen the most recent analyst activity on August 11, 2025, when Wedbush initiated its Outperform rating and assigned the stock a price target of $28. On July 24, 2025, Canaccord Genuity initiated with a Buy rating and assigned a price target of $28 on the stock. Oppenheimer started tracking the stock assigning an Outperform rating and suggested a price target of $30 on December 06, 2024. UBS initiated its recommendation with a Buy and recommended $12 as its price target on November 12, 2024. Goldman downgraded its rating to Neutral for this stock on June 28, 2024, and downed its price target to $6. In a note dated May 02, 2024, H.C. Wainwright initiated a Buy rating and provided a target price of $32 on this stock.
Sagimet Biosciences Inc [SGMT] stock has fluctuated between $1.73 and $11.41 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Sagimet Biosciences Inc [NASDAQ: SGMT] shares were valued at $6.24 at the most recent close of the market. An investor can expect a potential drop of -3.85% based on the average SGMT price forecast.
Analyzing the SGMT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.45, Equity is -0.42 and Total Capital is -0.54. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Sagimet Biosciences Inc’s Current Ratio is 13.04. On the other hand, the Quick Ratio is 13.04, and the Cash Ratio is 3.55.
Transactions by insiders
Recent insider trading involved Kemble George, Executive Chairman, that happened on Nov 20 ’25 when 37688.0 shares were sold. Director, GEORGE KEMBLE completed a deal on Nov 20 ’25 to buy 37688.0 shares. Meanwhile, President & CEO Happel David sold 65478.0 shares on Jul 21 ’25.
